Immediate Impact
57 standout
Citing Papers
Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers
2024 Standout
Tumor biomarkers for diagnosis, prognosis and targeted therapy
2024 Standout
Works of Christopher Herbert being referenced
Results of the OPARATIC trial: A phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM).
2017
ACTR-16. RESULTS OF THE OPARATIC TRIAL: A PHASE I DOSE ESCALATION STUDY OF OLAPARIB IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN PATIENTS WITH RELAPSED GLIOBLASTOMA (GBM)
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Christopher Herbert | 159 | 110 | 79 | 96 | 34 | 399 | |
| J M de Almeida | 141 | 79 | 59 | 21 | 20 | 438 | |
| Yanbing Zhang | 88 | 31 | 58 | 26 | 34 | 349 | |
| Jackie Johnson | 65 | 39 | 85 | 118 | 43 | 422 | |
| Fatma Ben Moussa | 102 | 68 | 8 | 36 | 35 | 354 | |
| Jon Carrick | 97 | 33 | 33 | 26 | 13 | 344 | |
| J. M. Ian Salas | 233 | 14 | 12 | 86 | 16 | 450 | |
| Jiro Honda | 82 | 22 | 22 | 14 | 43 | 342 | |
| Ryo Ishida | 131 | 35 | 10 | 7 | 40 | 375 | |
| Grace Gao | 69 | 8 | 81 | 89 | 25 | 400 | |
| Thomas Langer | 81 | 10 | 100 | 17 | 47 | 339 |
All Works
Loading papers...